Company Overview and News

 
Alkane Resources director Anthony Dean Lethlean snaps up more shares from the market

2018-09-17 proactiveinvestors.com.au
Alkane Resources Limited (ASX:ALK) director Anthony Dean Lethlean is continuing to demonstrate his confidence in the company via the acquisition of more shares.
ALKEF ANLKY ALK

 
Alkane Resources director shows faith in multi-commodity strategy with on-market share purchase

2018-09-10 proactiveinvestors.com.au
Alkane Resources Limited (ASX:ALK) director Anthony Dean Lethlean has demonstrated his confidence in the company’s multi-commodity strategy by acquiring shares on-market.
ALKEF ANLKY ALK

 
Alkane Resources' financing and offtake talks on Dubbo Project helped by new US law

2018-08-23 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) managing director Nic Earner tells Proactive Investors that the new US Defense ban preventing the purchase of rare earth magnets from China, which currently produces 85-90% of the world’s supply, could mark a windfall for the NSW-focused company.
ALKEF ANLKY ALK

 
Alkane Resources leveraged to US rare earths purchase bans which create new demand potential

2018-08-17 proactiveinvestors.com.au
Alkane Resources Limited (ASX:ALK) is leveraged to the new US defence law that prevents the purchase of rare earth magnets from prohibited countries, like China, Russia, North Korea and Iran.
ALKEF ANLKY ALK

 
Alkane Resources’ gold drilling results confirm near-mine potential at Tomingley

2018-07-11 proactiveinvestors.com.au
Alkane Resources Limited’s (ASX:ALK) recent drilling has intersected high-grade gold intercepts at the Roswell Prospect, part of its Tomingley Gold Operations (TGO) in New South Wales.
ALKEF ANLKY ALK

 
Alkane Resources says 'demand must come' for rare earths as EV revolution continues

2018-06-25 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) managing director Nic Earner speaks to Proactive Investors about the junior exploration and mining company's multi-commodity portfolio of NSW projects; which includes the cash-generating Tomingley Gold Mine, the construction-ready Dubbo Project, and regional exploration.
ALKEF ANLKY ALK

 
Alkane Resources says 'demand must come' for zirconium as EV revolution continues

2018-06-25 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) managing director Nic Earner speaks to Proactive Investors about the junior exploration and mining company's multi-commodity portfolio of NSW projects; which includes the cash-generating Tomingley Gold Mine, the construction-ready Dubbo Project, and regional exploration.
ALKEF ANLKY ALK

 
Alkane Resources director buys one million shares on-market

2018-06-07 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) has received a vote of confidence from its technical director David Chalmers who has purchased one million shares in the company.
ALKEF ANLKY ALK

 
Alkane Resources confirms up to $1.2 billion valuation for Dubbo Project

2018-06-04 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) has completed an engineering and financials review of its zirconium, niobium, hafnium and rare earths project, the Dubbo Project in New South Wales.
ALKEF ANLKY ALK

4
Alkane Resources is an award winning gold miner with a multi-commodity construction-ready project

2018-03-26 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) has used its cash-generating Tomingley Gold Operation (TGO) in New South Wales to advance its Dubbo Project to a construction-ready stage.
ALKEF MALRY ANLKY ALK MALRF MIN

 
Alkane Resources wins mining operation of the year award

2018-03-20 proactiveinvestors.com.au
Alkane Resources Ltd (ASX:ALK) was recently awarded mining operation of the year as part of the New South Wales Minerals Council Suppliers Awards.
ALKEF ANLKY ALK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:ALK / ALKANE RESOURCES LIMITED on message board site Silicon Investor.

Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Z Best Place to Talk Stocks Z Best Place to Talk Stocks Z Best Place to Talk Stocks
Bob Brinker, Moneytalk and Marketimer Bob Brinker, Moneytalk and Marketimer Bob Brinker, Moneytalk and Marketimer Walking for Health, Weight Loss or Pleasure Walking for Health, Weight Loss or Pleasure Walking for Health, Weight Loss or Pleasure
Diabetes, letu0027s talk about it Diabetes, letu0027s talk about it Diabetes, letu0027s talk about it Letu0027s Talk About the War Letu0027s Talk About the War Letu0027s Talk About the War
Bosco u0026 Crossyu0027s stock picks,talk area Bosco u0026 Crossyu0027s stock picks,talk area Bosco u0026 Crossyu0027s stock picks,talk area Talk City Inc - (Nasdaq-TCTY) Talk City Inc - (Nasdaq-TCTY) Talk City Inc - (Nasdaq-TCTY)
Letu0027s Talk About Our Feelings!!! Letu0027s Talk About Our Feelings!!! Letu0027s Talk About Our Feelings!!! Let���s Talk About Our Feelings about the Let���s Talk About Our Let���s Talk About Our Feelings about the Let���s Talk About Our Let���s Talk About Our Feelings about the Let���s Talk About Our